Free Trial

Daxor (DXR) Competitors

Daxor logo
$8.06 -0.13 (-1.59%)
As of 03/26/2025 03:44 PM Eastern

DXR vs. LNSR, AVR, CATX, PDEX, OBIO, SGHT, STIM, INFU, KRMD, and ZJYL

Should you be buying Daxor stock or one of its competitors? The main competitors of Daxor include LENSAR (LNSR), Anteris Technologies Global (AVR), Perspective Therapeutics (CATX), Pro-Dex (PDEX), Orchestra BioMed (OBIO), Sight Sciences (SGHT), Neuronetics (STIM), InfuSystem (INFU), KORU Medical Systems (KRMD), and Jin Medical International (ZJYL). These companies are all part of the "medical equipment" industry.

Daxor vs.

Daxor (NASDAQ:DXR) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations.

Daxor has higher earnings, but lower revenue than LENSAR.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Daxor$2.13M18.30N/AN/AN/A
LENSAR$53.49M3.12-$14.38M-$2.72-5.20

Daxor has a net margin of 0.00% compared to LENSAR's net margin of -34.03%. Daxor's return on equity of 0.00% beat LENSAR's return on equity.

Company Net Margins Return on Equity Return on Assets
DaxorN/A N/A N/A
LENSAR -34.03%-49.02%-21.12%

Daxor currently has a consensus target price of $25.00, indicating a potential upside of 210.17%. LENSAR has a consensus target price of $15.00, indicating a potential upside of 6.08%. Given Daxor's stronger consensus rating and higher probable upside, research analysts plainly believe Daxor is more favorable than LENSAR.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Daxor
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
LENSAR
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

LENSAR received 4 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 40.00% of users gave LENSAR an outperform vote.

CompanyUnderperformOutperform
DaxorOutperform Votes
2
100.00%
Underperform Votes
No Votes
LENSAROutperform Votes
6
40.00%
Underperform Votes
9
60.00%

1.3% of Daxor shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 59.0% of Daxor shares are owned by company insiders. Comparatively, 38.5% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, LENSAR had 11 more articles in the media than Daxor. MarketBeat recorded 13 mentions for LENSAR and 2 mentions for Daxor. Daxor's average media sentiment score of 1.44 beat LENSAR's score of 0.42 indicating that Daxor is being referred to more favorably in the media.

Company Overall Sentiment
Daxor Positive
LENSAR Neutral

Daxor has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

Summary

Daxor beats LENSAR on 10 of the 15 factors compared between the two stocks.

Remove Ads
Get Daxor News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXR vs. The Competition

MetricDaxorSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$38.99M$4.42B$5.63B$8.15B
Dividend YieldN/A32.62%4.55%4.00%
P/E RatioN/A28.7924.4919.08
Price / Sales18.3049.55385.2994.58
Price / CashN/A51.0838.1634.64
Price / BookN/A6.166.954.36
Net IncomeN/A$67.64M$3.20B$247.23M
7 Day Performance-2.54%-0.66%-2.42%-0.61%
1 Month Performance4.13%-2.43%2.18%-5.12%
1 Year Performance-6.82%19.33%12.85%3.60%

Daxor Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXR
Daxor
3.9597 of 5 stars
$8.06
-1.6%
$25.00
+210.2%
-6.8%$38.99M$2.13M0.0037Positive News
Gap Up
LNSR
LENSAR
0.7686 of 5 stars
$14.13
-0.8%
$15.00
+6.2%
+299.4%$166.56M$53.49M-9.68110Analyst Forecast
High Trading Volume
AVR
Anteris Technologies Global
N/A$4.62
-9.8%
$16.50
+257.1%
N/A$166.43M$2.71M0.00138News Coverage
Gap Up
CATX
Perspective Therapeutics
2.9115 of 5 stars
$2.45
-3.0%
$14.56
+495.3%
N/A$165.25M$1.43M0.0070Analyst Forecast
PDEX
Pro-Dex
1.3494 of 5 stars
$50.38
+0.8%
$52.00
+3.2%
+186.9%$164.29M$61.00M25.06140Insider Trade
Short Interest ↑
OBIO
Orchestra BioMed
1.7115 of 5 stars
$4.29
-6.2%
$15.40
+259.4%
-16.7%$162.89M$2.65M-2.664
SGHT
Sight Sciences
3.1872 of 5 stars
$2.83
-8.0%
$3.83
+35.7%
-46.9%$145.02M$79.87M-2.77210Short Interest ↑
STIM
Neuronetics
2.1175 of 5 stars
$4.46
-4.6%
$5.50
+23.5%
-14.3%$136.45M$74.89M-3.66180Short Interest ↑
INFU
InfuSystem
1.9044 of 5 stars
$6.12
+0.7%
$13.00
+112.6%
N/A$128.47M$134.86M101.93410
KRMD
KORU Medical Systems
2.7484 of 5 stars
$2.76
-2.1%
$4.70
+70.3%
+24.7%$126.61M$33.65M-11.0280
ZJYL
Jin Medical International
N/A$0.69
-5.4%
N/A-79.7%$107.24M$23.50M0.00245Gap Up
Remove Ads

Related Companies and Tools


This page (NASDAQ:DXR) was last updated on 3/27/2025 by MarketBeat.com Staff
From Our Partners